-- Topline Phase 1 data shows generally favorable safety and tolerability profile of Agmb-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of Agmb-447 in
Why Is AGMB (AGMB) Stock Down Today?
Updated Nov 22, 2026 6:21 AM ET ยท Prev Close $5.62
Session Regime & Catalyst Assessment
68% Signal ConvictionAGMB Pulling Back 3.02% on 0.59x Relative Volume
Agmb (Agmb) is pulling back 3.02% (-$0.17) to $5.45 on 0.59x average session volume. Relative to benchmarks, AGMB is outperforming the S&P 500 by +0.62%. 14-day RSI stands at 22.8, keeping momentum in a oversold regime.
-- Topline Phase 1 data shows generally favorable safety and tolerability profile of Agmb-447 -- -- Pharmacokinetic profile confirms efficient lung restriction with low systemic exposure and high exposure of Agmb-447 in
Price ($5.45) trades relative to 20-day SMA ($6.92) and 50-day SMA ($8.70).
Market & Sector Relative Strength
AGMB outperforming the S&P 500 by +0.62%Recent AGMB Catalyst Headlines
Verified WireAntwerp, Belgium, November 4, 2026 Agomab Therapeutics NV Nasdaq AGMB Agomab , a clinical-stage biopharmaceutical company focused on fibro-inflammation, today announced that members of the management team will participat
-- Nov-Era is designed to assess the efficacy and safety of ontunisertib in approximately 320 patients with symptomatic Fibrostenosing Crohn's disease Fscd -- -- Global, randomized, placebo-controlled, dose-ranging study
-- Open-Label Extension OLE Data of Stenova Phase 2a study with ontunisertib in Fibrostenosing Crohn s disease FSCD selected for oral presentation at UEG Week 2026 -- -- Results support initiation of global Nov-Era Phase
1โ3 Day Expected Range & Key Level
48% Follow-ThroughMonitor volume expansion above 1.5x RVOL around $5.39 (session support) for directional breakout confirmation.
Technical Regime (AGMB)
BEARISH MA TRENDAbout AGMB
Get Instant AGMB Catalyst Alerts
Receive an email alert when AGMB triggers an unusual volume breakout, options sweep, or rating shift.
AGMB Session & Catalyst FAQ
Why is AGMB stock down today?
Agmb (Agmb) is pulling back 3.02% (-$0.17) to $5.45 on 0.59x average session volume. Relative to benchmarks, AGMB is outperforming the S&P 500 by +0.62%. 14-day RSI stands at 22.8, keeping momentum in a oversold regime.
Is AGMB stock a buy or sell right now?
Today's session carries a 68% catalyst conviction score on 0.59x relative volume (low participation). Our multi-factor model currently rates AGMB as HOLD. Review full valuation, quality, and timing signals on the AGMB Buy or Sell Decision Brief โ
What is AGMB's intrinsic value and expected trading range?
At $5.45, AGMB's modeled 1-to-3 session range is $5.15 โ $5.75, with a key inflection level at $5.39 (session support). Compare current price against multi-year cash flow projections in the AGMB Intrinsic Value & DCF Model โ and Market Cycle Phase Tracker โ
What do RSI and moving averages signal for AGMB?
RSI at 22.8 indicates oversold conditions โ watch for mean-reversion support. AGMB trades at $5.45 relative to its 20-day SMA ($6.92) and 50-day SMA ($8.70), reflecting a bearish moving-average structure.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.